Accéder au contenu
Merck

Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues.

Nature communications (2022-07-20)
Qi Song, Ye Yang, Dongxian Jiang, Zhaoyu Qin, Chen Xu, Haixing Wang, Jie Huang, Lingli Chen, Rongkui Luo, Xiaolei Zhang, Yufeng Huang, Lei Xu, Zixiang Yu, Subei Tan, Minying Deng, Ruqun Xue, Jingbo Qie, Kai Li, Yanan Yin, Xuetong Yue, Xiaogang Sun, Jieakesu Su, Fuchu He, Chen Ding, Yingyong Hou
RÉSUMÉ

Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are two main histological subtypes of solid cancer; however, SCCs are derived from different organs with similar morphologies, and it is challenging to distinguish the origin of metastatic SCCs. Here we report a deep proteomic analysis of 333 SCCs of 17 organs and 69 ACs of 7 organs. Proteomic comparison between SCCs and ACs identifies distinguishable pivotal pathways and molecules in those pathways play consistent adverse or opposite prognostic roles in ACs and SCCs. A comparison between common and rare SCCs highlights lipid metabolism may reinforce the malignancy of rare SCCs. Proteomic clusters reveal anatomical features, and kinase-transcription factor networks indicate differential SCC characteristics, while immune subtyping reveals diverse tumor microenvironments across and within diagnoses and identified potential druggable targets. Furthermore, tumor-specific proteins provide candidates with differentially diagnostic values. This proteomics architecture represents a public resource for researchers seeking a better understanding of SCCs and ACs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-p16, clone D25, clone D25, Chemicon®, from mouse